At least 24 children have died in India after consuming Coldrif cough syrup, raising renewed concerns about the country’s pharmaceutical safety standards. Investigations indicate that the propylene glycol (PG) solvent used to produce the syrup may have been contaminated with diethylene glycol (DEG), a toxic chemical. Indian authorities are probing the supply chain, which involved multiple distributors and a small fragrance company, to determine how the contamination occurred.
WHY IT MATTERS
The incident highlights systemic weaknesses in India’s $50 billion pharmaceutical industry, including inadequate oversight of chemical suppliers and repackaging practices. DEG, sometimes fraudulently or unintentionally substituted for PG, can cause acute kidney damage and death in children. These deaths echo previous incidents in 2022 and 2023, when Indian-made cough syrups caused over 140 fatalities in Africa and Central Asia. Weak regulatory enforcement, combined with unsafe handling of pharmaceutical ingredients, poses a global health risk.
Key actors include Sresan Pharmaceutical Manufacturer, whose license has been revoked and founder G. Ranganathan is in custody; the chemical suppliers Sunrise Biotech and Jinkushal Aroma; Tamil Nadu state regulators; and India’s Central Drugs Standard Control Organisation. International suppliers like South Korea’s SK picglobal are indirectly implicated, as repackaging of their sealed products may have compromised quality. Families of affected children, public health authorities, and global pharmaceutical watchdogs are also stakeholders.
IMPLICATIONS
The deaths could erode trust in India’s pharmaceutical sector, which is a major global supplier of generic medicines. International buyers may impose stricter quality checks or halt imports, affecting India’s exports and reputation. Domestically, the tragedy could prompt tighter regulations, more frequent inspections, and harsher penalties for non-compliant drugmakers. Public confidence in pediatric medicines may also decline, potentially impacting vaccination and treatment programs if safety concerns persist.
WHAT’S NEXT
Authorities are conducting inspections and reviewing the safety of pediatric cough syrups across India. Legal action against Sresan and potential regulatory reforms are expected to follow. Experts say stricter enforcement of handling and distribution rules for pharmaceutical-grade chemicals, combined with more frequent inspections, is crucial to prevent further fatalities. Globally, the case may prompt importers of Indian medicines to tighten quality checks.
With information from an exclusive Reuters report.
